BAY 1128688

Drug Profile

BAY 1128688

Alternative Names: BAY1128688

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Anti-inflammatories
  • Mechanism of Action AKR1C3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometriosis

Most Recent Events

  • 18 Sep 2017 Phase-II clinical trials in Endometriosis in Spain (PO) (EudraCT2017-000244-18)
  • 30 Apr 2016 Bayer completes a phase I trial for Endometriosis in volunteers in Germany (NCT02434640)
  • 20 May 2015 Bayer initiates enrolment in a phase I trial for Endometriosis (In volunteers) in Germany (NCT02434640)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top